Transverse B-Lynch in Management of Placenta Accreta

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Placenta accreta is considered a severe pregnancy complication that may be associated with massive and potentially life-threatening intrapartum and postpartum hemorrhage. Life-threatening bleeding is the most common complication to be associated with this condition; the average blood loss at time of delivery is reported to be 3000-5500 mL, which leads to significant postoperative morbidity and death.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02943148` - Prediction of Pelvic Adhesions at Repeat Cesarean Delivery
	Completed	`NCT02943122` - Ambulatory Blood Pressure Monitoring in Post-Partum Pre-Eclamptic Patients

NCT number	NCT02943421
Study type	Observational
Source	Assiut University
Contact
Status	Completed
Phase
Start date	December 1, 2016
Completion date	May 5, 2018

Transverse B-Lynch in Management of Placenta Accreta

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms